MedTrace Logo

Effect Baroreflex Activation Therapy on the Carotid Body

NCT02210923 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-08-07

No results posted yet for this study

Summary

Carotid baroreflex activation therapy (BAT) by the Rheos® system produces a sustained fall in blood pressure in patients with resistant hypertension. Since the activation electrodes are implanted at the level of the carotid sinus, it is conceivable that the nearby located carotid body chemoreceptors are stimulated as well. Physiological stimulation of carotid chemoreceptors not only raises respiration, but it also increases sympathetic activity which may in part counteract the effects of BAT. The aim of the present study is to investigate whether there is evidence for concomitant carotid chemoreflex activation during BAT. We hypothesized that there is no clinically relevant co-activation of the carotid body chemoreceptors during BAT in patients with resistant hypertension.

Conditions

  • Hypertension Resistant To Conventional Therapy
  • Baroreflex
  • Carotid Body

Sponsors & Collaborators

  • CVRx, Inc.

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Abraham Kroon, MD, PhD · Maastricht University Medical Center

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210923 on ClinicalTrials.gov